116239 - An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix® in the United Kingdom | HMA-EMA Catalogues of real-world data sources and studies

Study protocol

Initial protocol

EPI-HPV-040 VS UK (116239) Protocol (FDA - EMA PASS) (09-Jul-2013)_PASS Registry

English (654.31 KB - PDF) View document

Study results

gsk-116239-clinical-study-report_1-redact

English (1.12 MB - PDF) View document

Study report

gsk-116239-clinical-study-report_2-redact

English (1.52 MB - PDF) View document

gsk-116239-clinical-study-report_3-redact

English (1.6 MB - PDF) View document

gsk-116239-clinical-study-report_4-redact

English (1.97 MB - PDF) View document

Other information

Study, other information

gsk-116239-clinical-study-report_3-redact.pdf

English (1.6 MB - PDF) View document

gsk-116239-clinical-study-report_4-redact.pdf

English (1.97 MB - PDF) View document

116239 - An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix® in the United Kingdom